Combination therapy in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 13, Issue 3, 2001, Pages 177-183

  Goekoop, Yvonne P M ^a,b   Allaart, Renée C F ^b   Breedveld, Ferdinand C ^b   Dijkmans, Ben A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; COLLAGEN TYPE 2; CORTICOSTEROID; CYCLOSPORIN A; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TETRACOSACTIDE; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; JOINT DESTRUCTION; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME;

EID: 0035002969     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200105000-00005     Document Type: Review

References (47)

1. 1 Wilske KR, Healey LA: Remodeling the pyramid-a concept whose time has come. J Rheumatol 1989, 16:565-567.
2. 2 Pincus T, Callahan LF, Sale WG, et al.: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984, 27:864-872.
3. 3 Scott DL, Symmons DP, Coulton BL, et al.: Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987, 1:1108-1111.
4. 4 Rasker JJ, Cosh JA: Course and prognosis of early rheumatoid arthritis. Scand J Rheumatol 1989, (suppl) 79:45-56.
5. 5 van der Heijde DM, van Riel PL, van Leeuwen MA, et al.; Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 1992, 31:519-525.
6. 6 Fries JF, Spitz PW, Williams CA, et al.: A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990, 33:121-130.
7. 7 Fries JF, Williams CA, Bloch DA: The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1991, 34:1353-1360.
8. 8 Fries JF, Williams CA, Ramey D, et al.: The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993, 36:297-306.
9. 9 Fries JF: Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol 1990, 22 (suppl):12-15.
10. 10 Sokka T, Hannonen P: Utility of disease modifying antirheumatic drugs in "sawtooth" strategy: a prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 1999, 58:618-622.
11. 11 Sokka T, Möttönen T, Hannonen P: Disease-modifying anti-rheumatic drug use according to the "sawtooth" treatment strategy improves the functional outcome in rheumatoid arthritis: results of a long-term follow-up study with review of the literature. Rheumatology (Oxford) 2000, 39:34-42.
12. 12 Scott DL, Farrow S, Yeo SI: Early developments in combination therapy. Clin Exp Rheumatol 1999, 17:S8-12.
13. 13 Siever K, Hurri L: Combined therapy of rheumatoid arthritis with gold and chloroquine, I Evaluation of the therapeutic effect. Acta Rheum Scand 1963, 9:948-955.
14. 14 Felson DT, Anderson JJ, Meenan RF: The efficacy and toxicity of combination therapy in rheumatoid arthritis; a meta-analysis. Arthritis Rheum 1994, 37:1487-1491.
15. 15 Verhoeven AC, Boers M, Tugwell P: Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998, 37:612-619.
16. 16 Anderson JJ, Wells G, Verhoeven AC, et al.: Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000, 43:22-29.
17. 17 van der Heide A, Jacobs JW, Bijlsma JW, et al.: The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996, 124:699-707.
18. 18 Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al.: Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year follow-up on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000, 27:623-629. This study demonstrates the importance of early treatment with DMARDs.
19. 19 Dougados M, Combe B, Cantagrel A, et al.: Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999, 58:220-225.
20. 20 Haagsma CJ, van Riel PL, de Jong AJ, et al.: Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997, 36:1082-1088.
21. 21 Möttönen T, Hannonen P, Leirisalo-Repo M, et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999, 353:1568-1573. In this study, the beneficial efficacy of the combination of methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone above monotherapy in patients with early RA is demonstrated.
22. 22 Calgüneri M, Pay S, Caliskaner Z, et al.: Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. C in Exp Rheumatol 1999, 17:699-704.
23. 23 Drosos AA, Voulgari PV, Papadopoulos IA, et al.: Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. Clin Exp Rheumatol 1998, 16:695-701.
24. 24 Drosos AA, Voulgari PV, Katsaraki A, et al.: Influence of cyclosporin A on radiologic progression in early rheumatoid arthritis patients: a 42-month prospective study. Rheumatol Int 2000, 19:113-118.
25. 25 Proudman SM, Conaghan PG, Richardson C, et al.: Treatment of poor-prognosis early rheumatoid arthritis: a randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000, 43:1809-1819.
26. 26 Keyszer G, Keysser C, Keysser M: Efficacy and safety of a combination therapy of methotrexate, chloroquine and cyclophosphamide in patients with refractory rheumatoid arthritis: results of an observational study with matched-pair analysis. Clin Rheumatol 1999, 18:145-151.
27. 27 Rau R: Combination DMARD treatment with parenteral gold and methotrexate. Clin Exp Rheumatol 1999, 17:S83-90.
28. 28 Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259. This study shows that the combination of a TNF-α blocking agent and methotrexate offers more rapid and greater clinical improvement compared with methotrexate monotherapy in patients with long-term RA.
29. 29 Kremer JM, Weinblatt ME, Fleischman RM, et al.: Etanercept (Enbrel) in addition to methotrexate (MTX) in rheumatoid arthritis (RA): long-term observations [abstract]. Arthritis Rheum 2000, 43:S270.
30. 30 Lipsky PE, van der Heijde DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602. The sustained clinical efficacy as well as the sustained prevention of erosions of the combination of methotrexate and a TNF-α blocking agent in patients with chronic RA is demonstrated.
31. 31 Maini R, St Clair EW, Breedveld F, et al.: Infliximab (chimeric anti-tumor necrosis factor alpha-monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939. This study shows the superiority of the combination of a TNF-α blocking agent and methotrexate above methotrexate alone in patients with chronic RA during the first 30 weeks of treatment.
32. 32 Lipsky P, van der Heijde D, St Clair W, et al.: 102-week clinical & radiologic results from the ATTRACT trial: a 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade) in patients with active RA despite MTX [abstract]. Arthritis Rheum 2000, 43:S269.
33. 33 McKown KM, Carbone LD, Kaplan SB, et al.: Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum 1999, 42:1204-1208.
34. 34 Taylor WJ, Rajapakse CN, Harris KA, et al.: Inpatient treatment of rheumatoid arthritis with synacthen depot: a double blind placebo controlled trial with 6 month follow-up. J Rheumatol 1999, 26:2544-2550.
35. 35 Irvine S, Munro R, Porter D: Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Ann Rheum Dis 1999, 58:510-513.
36. 36 O'Dell J: Combination DMARD therapy for rheumatoid arthritis: apparent universal acceptance [abstract]. Arthritis Rheum 1997, 40:S50.
37. 37 Emery P, Marzo H, Proudman S: Management of patients with newly diagnosed rheumatoid arthritis. Rheumatology (Oxford) 1999, 38 (suppl 2):27-31.
38. 38 Fries JF: Current treatment paradigms in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39 (suppl 1):30-35.
39. 39 O'Dell JR, Scott DL: Rheumatoid arthritis: new developments in the use of existing therapies. Rheumatology (Oxford) 1999, 38 (suppl 2):24-26.
40. 40 Pincus T, O'Dell JR, Kremer JM: Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999, 131:768-774.
41. 41 Simon LS, Yocum D: New and future drug therapies for rheumatoid arthritis. Rheumatology (Oxford) 2000, 39 (suppl 1):36-42.
42. 42 Weinblatt ME: The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999, 38 (suppl 2):19-23.
43. 43 Furst DE: Aggressive strategies for treating aggressive rheumatoid arthritis: has the case been proven? Lancet 2000, 356:183-184.
44. 44 O'Dell JR, Haire CE, Erikson N, et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and nydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-1291.
45. 45 Tugwell P, Pincus T, Yocum D, et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995, 333:137-141.
46. 46 Boers M, Verhoeven AC, Markusse HM, et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [erratum appears in Lancet 1998,351:220]. Lancet 1997, 350:309-318.
47. 47 Landewe RBM, Boers M, Verhoeven AC: Legacy of COBRA combination therapy: gain in damage control is probably permanent [abstract]. Arthritis Rheum 2000, 43:S382.